Group 1 - The core point of the article is that Duori Pharmaceutical announced a share repurchase plan, allowing the company to sell back its repurchased shares within a specified timeframe [1] - The company plans to sell up to approximately 1.04 million shares, which represents 1.31% of its total share capital, with the sale price determined by the secondary market [1] - The board meeting to approve this plan is scheduled for December 19, 2025, and the sale period will be from January 14, 2026, to July 13, 2026 [1] Group 2 - For the year 2024, Duori Pharmaceutical's revenue composition is 57.85% from the pharmaceutical manufacturing sector and 42.15% from other sources [1] - As of the latest report, the market capitalization of Duori Pharmaceutical is 4.1 billion yuan [2]
多瑞医药：公司拟出售回购股份不超过约104万股